Latest Insider Transactions at Sierra Oncology, Inc. (SRRA)
This section provides a real-time view of insider transactions for Sierra Oncology, Inc. (SRRA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Sierra Oncology, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Sierra Oncology, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 01
2022
|
Stephen George Dilly CEO and President |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,000
-100.0%
|
$275,000
$55.0 P/Share
|
|
Jul 01
2022
|
Craig A Collard Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
13,500
-100.0%
|
$742,500
$55.0 P/Share
|
|
Jul 01
2022
|
Andrew R Allen Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,650
-100.0%
|
$90,750
$55.0 P/Share
|
|
Jul 01
2022
|
Barbara Klencke Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
5,000
-100.0%
|
$275,000
$55.0 P/Share
|
|
Jul 01
2022
|
Barbara Klencke Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,000
-100.0%
|
$550,000
$55.0 P/Share
|
|
Jul 01
2022
|
Andrew Sinclair Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,314,127
-100.0%
|
$72,276,985
$55.0 P/Share
|
|
Jul 01
2022
|
Gaurav Aggarwal Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
2,735,853
-100.0%
|
$150,471,915
$55.0 P/Share
|
|
Jul 01
2022
|
Mona Ashiya Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,964,770
-100.0%
|
$108,062,350
$55.0 P/Share
|
|
Jul 01
2022
|
Vivo Opportunity, LLC Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
3,329,512
-100.0%
|
$183,123,160
$55.0 P/Share
|
|
Jul 01
2022
|
Orbimed Advisors LLC Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,964,770
-100.0%
|
$108,062,350
$55.0 P/Share
|
|
Apr 27
2022
|
Longitude Capital Partners Iii, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
16,030
+29.74%
|
-
|
|
Apr 27
2022
|
Longitude Capital Partners Iii, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
2,139,771
-100.0%
|
-
|
|
Apr 06
2022
|
William D. Turner Chief Reg & Tech Ops Officer |
SELL
Open market or private sale
|
Direct |
6,347
-100.0%
|
$234,839
$37.25 P/Share
|
|
Apr 06
2022
|
William D. Turner Chief Reg & Tech Ops Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,347
+50.0%
|
$76,164
$12.05 P/Share
|
|
Apr 05
2022
|
William D. Turner Chief Reg & Tech Ops Officer |
SELL
Open market or private sale
|
Direct |
100
-100.0%
|
$3,700
$37.09 P/Share
|
|
Apr 05
2022
|
William D. Turner Chief Reg & Tech Ops Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100
+50.0%
|
$1,200
$12.05 P/Share
|
|
Apr 04
2022
|
Mary Christina Thomson General Counsel |
SELL
Open market or private sale
|
Direct |
2,000
-100.0%
|
$70,000
$35.14 P/Share
|
|
Apr 04
2022
|
Mary Christina Thomson General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+50.0%
|
$26,000
$13.04 P/Share
|
|
Mar 18
2022
|
William D. Turner Chief Reg & Tech Ops Officer |
SELL
Open market or private sale
|
Direct |
100
-100.0%
|
$3,700
$37.05 P/Share
|
|
Mar 18
2022
|
William D. Turner Chief Reg & Tech Ops Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100
+50.0%
|
$1,200
$12.05 P/Share
|
|
Mar 17
2022
|
William D. Turner Chief Reg & Tech Ops Officer |
SELL
Open market or private sale
|
Direct |
3,453
-100.0%
|
$127,761
$37.06 P/Share
|
|
Mar 17
2022
|
William D. Turner Chief Reg & Tech Ops Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,453
+50.0%
|
$41,436
$12.05 P/Share
|
|
Mar 04
2022
|
Mary Christina Thomson General Counsel |
SELL
Open market or private sale
|
Direct |
2,000
-100.0%
|
$60,000
$30.6 P/Share
|
|
Mar 04
2022
|
Mary Christina Thomson General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+50.0%
|
$26,000
$13.04 P/Share
|
|
Feb 07
2022
|
William D. Turner Chief Reg & Tech Ops Officer |
SELL
Open market or private sale
|
Direct |
10,000
-100.0%
|
$320,000
$32.32 P/Share
|
|
Feb 07
2022
|
William D. Turner Chief Reg & Tech Ops Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$120,000
$12.05 P/Share
|
|
Feb 04
2022
|
Mary Christina Thomson General Counsel |
SELL
Open market or private sale
|
Direct |
2,000
-100.0%
|
$58,000
$29.78 P/Share
|
|
Feb 04
2022
|
Mary Christina Thomson General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+50.0%
|
$26,000
$13.04 P/Share
|
|
Feb 02
2022
|
Joshua Richardson Director |
BUY
Open market or private purchase
|
Indirect |
175,000
+50.0%
|
$4,725,000
$27.0 P/Share
|
|
Feb 02
2022
|
Longitude Capital Partners Iii, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
175,000
+50.0%
|
$4,725,000
$27.0 P/Share
|
|
Jan 31
2022
|
Andrew Sinclair Director |
BUY
Open market or private purchase
|
Indirect |
150,000
+10.25%
|
$4,050,000
$27.0 P/Share
|
|
Jan 31
2022
|
Abingworth LLP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
150,000
+10.25%
|
$4,050,000
$27.0 P/Share
|
|
Jan 31
2022
|
Gaurav Aggarwal Director |
BUY
Open market or private purchase
|
Indirect |
800,000
+22.63%
|
$21,600,000
$27.0 P/Share
|
|
Jan 31
2022
|
Vivo Opportunity, LLC Director |
BUY
Open market or private purchase
|
Indirect |
800,000
+22.63%
|
$21,600,000
$27.0 P/Share
|
|
Jan 28
2022
|
Andrew Sinclair Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
287,471
+19.8%
|
$3,737,123
$13.2 P/Share
|
|
Jan 28
2022
|
Abingworth LLP > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
287,471
+19.8%
|
$3,737,123
$13.2 P/Share
|
|
Jan 26
2022
|
William D. Turner Chief Reg & Tech Ops Officer |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$135,000
$27.05 P/Share
|
|
Jan 26
2022
|
William D. Turner Chief Reg & Tech Ops Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$60,000
$12.05 P/Share
|
|
Jan 26
2022
|
Mary Christina Thomson General Counsel |
SELL
Open market or private sale
|
Direct |
2,000
-100.0%
|
$58,000
$29.0 P/Share
|
|
Jan 26
2022
|
Mary Christina Thomson General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+50.0%
|
$26,000
$13.04 P/Share
|
|
Jan 26
2022
|
Gaurav Aggarwal Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
480,277
+19.88%
|
$6,243,601
$13.2 P/Share
|
|
Jan 26
2022
|
Vivo Opportunity, LLC Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
612,437
+17.71%
|
$7,961,681
$13.2 P/Share
|
|
Jan 26
2022
|
Mona Ashiya Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
487,450
+19.88%
|
$6,336,850
$13.2 P/Share
|
|
Jan 26
2022
|
Orbimed Advisors LLC Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
487,450
+19.88%
|
$6,336,850
$13.2 P/Share
|
|
Jan 25
2022
|
Joshua Richardson Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
487,451
+19.88%
|
$6,336,863
$13.2 P/Share
|
|
Jan 25
2022
|
Longitude Capital Partners Iii, LLC > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
487,451
+19.88%
|
$6,336,863
$13.2 P/Share
|
|
Nov 24
2021
|
Craig A Collard Director |
BUY
Open market or private purchase
|
Direct |
7,899
+36.91%
|
$181,677
$23.09 P/Share
|
|
Nov 23
2021
|
Craig A Collard Director |
BUY
Open market or private purchase
|
Direct |
5,601
+50.0%
|
$123,222
$22.95 P/Share
|
|
May 19
2021
|
Stephen George Dilly CEO and President |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$85,000
$17.83 P/Share
|
|
Jan 29
2020
|
Orbimed Advisors LLC Director |
BUY
Conversion of derivative security
|
Indirect |
1,477,320
+50.0%
|
-
|